SCHEMBL2213866

SCHEMBL2213866

COc1ccc2cc(-c3cc4ccnn4c(Nc4ccc(NC(=O)c5ccc(CN)cc5)cc4)n3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 7/20 0.47
KLK1 P06870 2/20 0.47
KLK6 Q92876 2/20 0.47
PLAU P00749 8/20 0.46
PLAT P00750 5/20 0.45
KLKB1 P03952 2/20 0.43
SNCA P37840 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
LOX P28300 2/20 0.41
LOXL2 Q9Y4K0 2/20 0.41
PRSS1 P07477 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2212378 0.93 SNCA (0.49) PLGKLK1KLK6PLAUPLAT
SCHEMBL2216054 0.92 PLAU (0.39) PLGKLK1KLK6PLAUPLAT
SCHEMBL2214607 0.92 PLAU (0.46) PLGPLAUPLATSNCAKDM4E
SCHEMBL2213434 0.92 KLKB1 (0.45) PLGPLAUPLATKLKB1KDM4E
SCHEMBL2214976 0.91 MAPT (0.47) PLGPLAUPLATKDM4EALDH1A1
SCHEMBL2215189 0.90 PLAU (0.50) PLGPLAUPLATSNCAKDM4E
SCHEMBL2216428 0.90 ALDH1A1 (0.41) PLGKLK1PLAUPLATKLKB1
SCHEMBL2216207 0.89 PLAU (0.44) PLGKLK1KLK6PLAUPLAT
SCHEMBL2213749 0.88 NPC1 (0.44) KDM4EALDH1A1MAPTHPGDLMNA
SCHEMBL2213349 0.85 PLAU (0.48) PLGPLAUPLATSNCAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 PLG 4568/4885KLK1 4282/4885KLK6 4438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.